Second tranche added. Very unloved this stock isn't it |
Good data. Stock price chart suggests the yanks are the ones trading on the short side here |
 GSK PLC on Tuesday reported "positive" data for testing on three different treatments by ViiV Healthcare, its majority-owned specialist HIV company.
The London-based pharmaceutical company firstly said ViiV Healthcare has shared 48-week findings from the phase 4 Paso Doble clinical trial investigating the two-drug regimen Dovato compared with the three-drug regimen Biktarvy for HIV.
Dovato comprises dolutegravir and lamivudine, while the Biktarvy regimen consists of bictegravir, emtricitabine and tenofovir alafenamide fumarate.
The trial, GSK said, focused on patients "who are virologically suppressed and who could benefit from treatment optimisation".
The 48-week results showed that virologically suppressed adults with HIV, if they switched to the Dovato regimen, demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to Biktarvy.
Secondly GSK said ViiV, in which Pfizer Inc and Shionogi & Co Ltd also hold minority interests, announced positive data for HIV drug Apretude, or cabotegravir LA for PrEP, in pregnant people.
The new maternal safety and pregnancy outcomes and pharmacokinetic findings came from the HIV Prevention Trials Network's 084 open label extension, which evaluated cisgender women in sub-Saharan Africa who became pregnant while using Apretude for HIV pre-exposure prophylaxis, or PrEP.
"The findings showed that [Apretude] was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period," GSK said.
Finally, GSK and ViiV announced phase 1 study results and in vitro data for VH4524184 or VH184, an investigational integrase strand transfer inhibitor or INSTI.
ViiV, GSK said, shared positive in vitro findings showing that VH184 retained its antiviral activity and could be effective in countering second-generation INSTI resistance.
Analysis of the phase 1 study, meanwhile, showed that PK and safety data supported the further development of VH184.
"The study showed VH184 achieved drug levels in the blood that could potentially exhibit sufficient antiviral activity against the clinically derived INSTI mutations seen in vitro," GSK explained. |
Morgan Stanley cuts target price to 1800p from 1860p |
GlaxoSmithKline (GSK) has announced the European Medicines Agency’s acceptance of their marketing application for Blenrep, a treatment for relapsed or refractory multiple myeloma. Promising results from two phase III trials, DREAMM-7 and DREAMM-8, indicated significant improvements in progression-free survival when compared to standard care. If approved, Blenrep could notably change the treatment landscape for this challenging blood cancer. |
IN @ 1520.928 ...... ;0) |
Bought a first Tranche at a smidge under 1508p |
Looking to make a first ever purchase here, but it looks like we are going to have a long summer on the UK stock market based on the last week or so. Dreadful performance despite massive undervaluation everywhere |
Drugs giant GSK is set to move its global headquarters back to central London, ending more than two decades at its Brentford base.
Around 3,000 employees will work from The Earnshaw building on the corner of New Oxford Street from Tuesday.
It marks the end of its time at the Brentford site in west London after the £315 million building was officially opened in 2002 by then prime minister Tony Blair.
GSK’s new HQ will house the firm’s leadership team – headed by chief executive Dame Emma Walmsley – as well as units supporting research and development, supply chain, commercial operations, corporate functions and its ViiV Healthcare specialist HIV joint venture.
It sees GSK return to central London, where the company traces its roots back to the Plough Court Pharmacy, founded in the City in 1715.
GSK said on announcing the new global HQ in December 2022 that the six-floor building would be designed with hybrid working in mind, including technology to support remote working, while also aiming to be energy efficient to help meet the firm’s 2030 net zero goals.
Dame Emma said at the time: “We are proud to call London our home and look forward to the opportunities for even closer collaboration with the city’s world-class science, academic and healthcare institutions.” |
Aug 23rd .... FDA decision on Jemperli Ph 3 RUBY trial |
No! Very good. ;) |
Good day Alphorn
"GSK have anything for this huge market?"
==========================================
Was the pun intended? |
Thx. Forgot about Alli. We don't hear much about that product; think that it has already gone generic? |
Take a look at GSK's alli® (orlistat 60 mg), launched 2009 |
For Pfizer holders - Pfizer is planning to test a daily weight-loss pill in mid-stage trials later this year on the experimental drug as its route into a market projected to be worth more than $130bn a year. The New York-based drugmaker said on Thursday that it would begin studies to evaluate the optimal dose of the weight-loss pill in the second half of this year. The pill is based on the compound danuglipron — a glucagon-like peptide, or GLP-1, similar to those used in popular weight-loss drugs produced by Novo Nordisk and Eli Lilly.
GSK have anything for this huge market? |
Guggenheim cuts target price to 1922p from 2092p |
Around 5% loss, bought in at 1600ish, can't see this moving anytime soon. |
What % did you lose? |
Dumped out of this, bought more 3i. Sell your losers, put them in your winners I say. |
Usually true but this one is a combination of downgraded vaccine market penetration and Zantac. Win the appeal and half that downgrade is then not pertinent |
"UBS cuts target price to 1580p from 2040p, neutral"
- a 460p cut is cannot be said to be neutral - negative at best.
These banks and brokers don't seem to have a clue. |
UBS cuts target price to 1580p from 2040p, neutral |
A mess of a company-one crises after another.....
A 4% dividend does not make up for it. |
That will probably be a successful appeal. Anyone have any idea when it's being heard? |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
